In patients with ACS and AF, NT‐proBNP is a potential biomarker to enhance risk discrimination for all‐cause death, cardiac death, and MACCE in combination with the CHA2DS2‐VASc score. This evidence concerns the gene NPPB and atrial fibrillation.